Condition

Acute Myeloid Leukemia, in Relapse clinical trials and research

• 21Clinical trials
• 16Countries

Newest Acute Myeloid Leukemia, in Relapse clinical trials

All recruiting trials (21)

• Personalized T-cell therapy with a DC/AML fusion vaccine plus decitabine and venetoclax for AML

  This will try combining a personalized T-cell therapy and a DC/AML fusion vaccine with decitabine and venetoclax for people with newly diagnosed or relapsed AML to see if it is safe and can boost anti-leukemia immunity.

  Recruiting Phase 1 Beth Israel Deaconess Medical Center · Boston, Massachusetts · NCT07374029

• Combining cytokine-induced memory-like natural killer cells with atezolizumab for relapsed or refractory AML

  This trial will test whether giving cytokine-induced memory-like natural killer cells together with atezolizumab is safe and might help adults with relapsed or refractory acute myeloid leukemia.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07011004

• Long-term safety follow-up of ARD103 CAR-T cells in relapsed/refractory AML and MDS

  This long-term follow-up study checks whether ARD103 CAR-T cell therapy remains safe for patients with relapsed or refractory AML or MDS after the initial treatment.

  Recruiting at 3 sites ARCE Therapeutics, Inc. · Charlotte, North Carolina and 2 other locations · NCT06906380

• Treatment with ARD103 CAR-T therapy for patients with relapsed or refractory AML or MDS

  This study is testing a new CAR-T therapy called ARD103 to see if it can help people with relapsed or hard-to-treat acute myeloid leukemia or myelodysplastic syndrome.

  Recruiting at 3 sites Phase 1/2 ARCE Therapeutics, Inc. · Charlotte, North Carolina and 2 other locations · NCT06680752

• MT-401-OTS treatment for relapsed AML or high‑risk MDS (safety focus)

  This trial will test whether escalating doses of an experimental off‑the‑shelf cell therapy called MT-401-OTS are safe and can reduce residual disease in adults aged 65 and older with relapsed or persistent AML or high‑risk MDS with low blast counts.

  Recruiting at 3 sites Phase 1 Marker Therapeutics, Inc. · Duarte, California and 2 other locations · NCT06552416

• Using Sorafenib to Prevent Relapse After Stem Cell Transplantation

  This study is testing if the drug sorafenib can help prevent relapse in patients with high-risk blood cancers after they receive a stem cell transplant.

  Recruiting Phase 2 St. Petersburg State Pavlov Medical University · Saint Petersburg · NCT06532084

• Framework for managing relapsed or refractory acute myeloid leukemia

  This study is trying to see how well new personalized treatments work for people in Europe with relapsed or refractory acute myeloid leukemia to help improve their care.

  Recruiting at 40 sites Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Aachen and 40 other locations · NCT06459024

• Investigating APL-4098 with Azacitidine for treating relapsed or refractory AML and high-risk MDS

  This study is testing a new treatment called APL-4098, alone and with azacitidine, to see if it can help people with relapsed or hard-to-treat acute myeloid leukemia and high-risk myelodysplastic syndrome.

  Recruiting at 8 sites Phase 1 Apollo Therapeutics Ltd · Clayton, Victoria and 8 other locations · NCT06372717

• Using off-the-shelf CAR-NK cells to treat relapsed or refractory acute myeloid leukemia

  This study is testing a new treatment using specially modified immune cells to see if they can help people with relapsed or hard-to-treat acute myeloid leukemia feel better.

  Recruiting Early Phase 1 Peking University People's Hospital · Beijing, Beijing Municipality · NCT06201247

• Using CAR-T cell therapy targeting Tim-3 and CD123 for treating relapsed acute myeloid leukemia

  This study is testing a new CAR-T cell therapy that targets specific markers in people aged 18-70 with relapsed acute myeloid leukemia to see if it can safely improve their treatment outcomes.

  Recruiting Phase 1/2 Xuzhou Medical University · Xuzhou, Jiangsu · NCT06125652

• Using CAR T cells to treat acute myeloid leukemia

  This study is testing a new treatment using specially modified CAR T cells to see if it can safely help adults and kids with tough cases of acute myeloid leukemia.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT06017258

• Treatment for patients with specific types of blood cancer using engineered T-cells

  This study is testing a new treatment using specially modified T-cells to see if it can help patients with a type of blood cancer called acute myeloid leukemia that hasn't responded to other therapies.

  Recruiting at 9 sites Phase 1 AvenCell Therapeutics, Inc. · Ulm, Baden-Wurttemberg and 14 other locations · NCT05949125

• Investigating Ziftomenib with Other Treatments for Acute Myeloid Leukemia

  This study is testing if a new drug called ziftomenib, when combined with other treatments, can help people with acute myeloid leukemia who have certain genetic mutations feel better and stay safe during treatment.

  Recruiting at 44 sites Phase 1 Kura Oncology, Inc. · Phoenix, Arizona and 43 other locations · NCT05735184

• Venetoclax plus bomedemstat for relapsed or refractory acute myeloid leukemia

  This trial tests whether giving bomedemstat together with venetoclax is safe and tolerable for adults whose acute myeloid leukemia has relapsed or not responded to prior treatment.

  Recruiting Phase 1 University of Miami · Miami, Florida · NCT05597306

• Combining venetoclax and 6-mercaptopurine for treating relapsed or refractory acute myeloid leukemia

  This study is testing if combining two drugs, venetoclax and 6-mercaptopurine, can help adults with relapsed or stubborn acute myeloid leukemia feel better.

  Recruiting Phase 1 University Hospital, Antwerp · Edegem, Antwerp and 1 other locations · NCT05506332

• Using venetoclax to improve treatment for relapsed or refractory acute myeloid leukemia

  This study is testing if adding a drug called venetoclax to existing treatments can help children, teens, and young adults with tough cases of acute myeloid leukemia feel better and have longer-lasting results.

  Recruiting Phase 1 Medical College of Wisconsin · Milwaukee, Wisconsin · NCT05317403

• AB8939 treatment for patients with relapsed or refractory acute myeloid leukemia

  This study is testing a new treatment called AB8939 to see if it can help people with relapsed or hard-to-treat acute myeloid leukemia feel better and improve their condition.

  Recruiting at 8 sites Phase 1/2 AB Science · Houston, Texas and 9 other locations · NCT05211570

• Evaluating BP1002 for patients with relapsed or refractory acute myeloid leukemia

  This study is testing a new treatment called BP1002 to see if it can help people with relapsed or refractory acute myeloid leukemia who haven't responded to other therapies.

  Recruiting at 4 sites Phase 1 Bio-Path Holdings, Inc. · La Jolla, California and 3 other locations · NCT05190471

• Analyzing the immune response in relapsed Acute Myeloid Leukemia after stem cell transplant

  This study is trying to understand how the immune system reacts when Acute Myeloid Leukemia comes back after a stem cell transplant, to help create better treatment plans for patients.

  Recruiting IRCCS San Raffaele · Milan, Milano · NCT05124288

• Using modified T cells to treat young patients with relapsed or refractory leukemia

  This study is testing a new treatment using modified T cells to see if it can help young patients with tough-to-treat leukemia feel better.

  Recruiting Phase 1 Seattle Children's Hospital · Seattle, Washington · NCT05105152

• C6 ceramide nanoliposome (CNL) treatment for relapsed or refractory acute myeloid leukemia

  This will test whether C6 ceramide delivered in a nanoliposome (CNL) by IV is safe for adults whose acute myeloid leukemia has relapsed or not responded to prior treatment.

  Recruiting Phase 1 Keystone Nano, Inc · Charlottesville, Virginia · NCT04716452

Related topics

Quick answers

How many Acute Myeloid Leukemia, in Relapse clinical trials are recruiting right now?

21, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 16 countries. The most sites are in United States (13 trials), Germany (2 trials), Italy (2 trials), Spain (2 trials), China (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 13, Phase 1/2: 3, Phase 2: 1, Early Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →